Cantor Fitzgerald Issues Positive Forecast for CRVS Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities researchers at Cantor Fitzgerald lifted their FY2026 EPS estimates for Corvus Pharmaceuticals in a research note issued to investors on Wednesday, November 5th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings per share of ($0.59) for the year, up from their previous estimate of ($0.69). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share.

CRVS has been the subject of a number of other research reports. Barclays started coverage on Corvus Pharmaceuticals in a research note on Monday, October 13th. They issued an “overweight” rating and a $16.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, October 8th. Mizuho set a $13.00 price target on shares of Corvus Pharmaceuticals in a research report on Wednesday, October 29th. Finally, Wall Street Zen cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, October 18th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.25.

Corvus Pharmaceuticals Stock Down 9.2%

Shares of NASDAQ:CRVS traded down $0.72 during trading on Friday, reaching $7.10. 434,086 shares of the company traded hands, compared to its average volume of 826,911. The firm has a market capitalization of $530.00 million, a PE ratio of -13.38 and a beta of 0.56. Corvus Pharmaceuticals has a 52 week low of $2.54 and a 52 week high of $10.00. The company’s 50 day moving average is $6.81 and its two-hundred day moving average is $5.07.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey bought a new stake in Corvus Pharmaceuticals during the 2nd quarter worth approximately $49,000. Sender Co & Partners Inc. acquired a new position in shares of Corvus Pharmaceuticals during the second quarter worth $52,000. ProShare Advisors LLC bought a new stake in shares of Corvus Pharmaceuticals in the second quarter worth $54,000. Shelton Wealth Management LLC acquired a new stake in Corvus Pharmaceuticals in the third quarter valued at $101,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Corvus Pharmaceuticals by 20.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 15,488 shares of the company’s stock worth $62,000 after purchasing an additional 2,599 shares during the last quarter. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.